SIREN : 820215341
GEPHARM is a French company founded 10 years ago, specialized in the sector Conseil pour les affaires et autres conseils de gestion. Based in PARIS (75008), this company of category PME shows in 2024 a revenue of 101 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 100 550 € | 116 800 € | 75 000 € | 67 000 € | 90 000 € | 90 000 € | 109 000 € |
| Net income | 15 037 € | 9 044 € | 1 483 € | -4 142 € | 16 331 € | 16 188 € | 4 705 € |
| EBITDA | 17 644 € | 19 043 € | 1 807 € | -3 382 € | 19 990 € | 19 496 € | 5 550 € |
| Net margin | 15.0% | 7.7% | 2.0% | -6.2% | 18.1% | 18.0% | 4.3% |
In 2024, GEPHARM achieves revenue of 101 k€. Activity remains stable over the period (CAGR: -1.1%). Significant drop of -14% vs 2023. After deducting consumption (0 €), gross margin stands at 101 k€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 18 k€, representing 17.5% of revenue. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 15 k€, i.e. 15.0% of revenue. This profit can be retained or distributed to shareholders.
100 550 €
100 550 €
17 644 €
17 643 €
15 037 €
17.5%
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 93%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 0.0 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 15.0% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
0.437%
92.946%
14.955%
0.016
In 2024, the debt ratio of GEPHARM (0.44) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
In 2024, the financial autonomy of GEPHARM (93.0%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
In 2024, the repayment capacity of GEPHARM (0.02) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 1504.38. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
1504.375
0.0
In 2024, the liquidity ratio of GEPHARM (1504.38) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2024, the interest coverage of GEPHARM (0.0x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 125 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 11 days. The gap of 114 days means the company finances its customers for over a month before being paid relative to supplier payments. This weighs on cash flow. Overall, WCR represents 105 days of revenue, i.e. 29 k€ to permanently finance. Over 2017-2024, WCR increased by +97%, requiring additional financing.
29 249 €
125 j
11 j
0 j
105 j
Based on 69 transactions of similar company sales
in 2024,
the value of GEPHARM is estimated at
78 270 €
(range 26 900€ - 134 261€).
With an EBITDA of 17 644€, the sector multiple of 4.3x is applied.
The price/revenue ratio is 0.66x
(in line with sector norms).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 69 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare GEPHARM with other companies in the same sector:
Voir toutes les statistiques du secteur Conseil pour les affaires et autres conseils de gestion
The revenue of GEPHARM in 2024 is 101 k€.
Yes, GEPHARM generated a net profit of 15 k€ in 2024.
The headquarters of GEPHARM is located in PARIS (75008), in the department Paris.
The tax return of GEPHARM is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
GEPHARM operates in the sector Conseil pour les affaires et autres conseils de gestion (NAF code 70.22Z). See the 'Sector positioning' section above to compare the company with its competitors.